C Lance Cowey1, Lisa Mahnke2, Janet Espirito3, Christoph Helwig4, Dina Oksen4, Murtuza Bharmal4. 1. Baylor Charles A. Sammons Cancer Center at Dallas, Texas Oncology, Dallas, TX 75246, USA. 2. EMD Serono, Inc, Billerica, MA 01821, USA. 3. McKesson Specialty Health, The Woodlands, TX 77380, USA. 4. Merck KGaA, Darmstadt, Germany.
Abstract
AIM: This retrospective study of patients in the USA with metastatic Merkel cell carcinoma (mMCC) aimed to assess patient responses to second-line and later (2L+) and first-line (1L) chemotherapy. PATIENTS & METHODS: Out of 686 patients with MCC identified in The US Oncology Network, 20 and 67 patients with mMCC qualified for the 2L+ and 1L study, respectively; the primary analysis population was restricted to immunocompetent patients. RESULTS: In the 2L+ primary analysis population, objective response rate (ORR) was 28.6%, median duration of response (DOR) was 1.7 months and median progression-free survival was 2.2 months. In the 1L primary analysis population, ORR was 29.4%, median DOR was 6.7 months and median progression-free survival was 4.6 months. CONCLUSION: The low ORR and brief DOR underscore the need for novel therapies.
AIM: This retrospective study of patients in the USA with metastatic Merkel cell carcinoma (mMCC) aimed to assess patient responses to second-line and later (2L+) and first-line (1L) chemotherapy. PATIENTS & METHODS: Out of 686 patients with MCC identified in The US Oncology Network, 20 and 67 patients with mMCC qualified for the 2L+ and 1L study, respectively; the primary analysis population was restricted to immunocompetent patients. RESULTS: In the 2L+ primary analysis population, objective response rate (ORR) was 28.6%, median duration of response (DOR) was 1.7 months and median progression-free survival was 2.2 months. In the 1L primary analysis population, ORR was 29.4%, median DOR was 6.7 months and median progression-free survival was 4.6 months. CONCLUSION: The low ORR and brief DOR underscore the need for novel therapies.
Authors: Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal Journal: Oncologist Date: 2019-04-08
Authors: Alexander Liede; Rohini K Hernandez; Sally W Wade; Ronghai Bo; Nathan C Nussbaum; Elizabeth Ahern; William C Dougall; Mark J Smyth Journal: Oncoimmunology Date: 2018-09-05 Impact factor: 8.110
Authors: Paul Nghiem; Shailender Bhatia; Evan J Lipson; William H Sharfman; Ragini R Kudchadkar; Andrew S Brohl; Phillip A Friedlander; Adil Daud; Harriet M Kluger; Sunil A Reddy; Brian C Boulmay; Adam I Riker; Melissa A Burgess; Brent A Hanks; Thomas Olencki; Kim Margolin; Lisa M Lundgren; Abha Soni; Nirasha Ramchurren; Candice Church; Song Y Park; Michi M Shinohara; Bob Salim; Janis M Taube; Steven R Bird; Nageatte Ibrahim; Steven P Fling; Blanca Homet Moreno; Elad Sharon; Martin A Cheever; Suzanne L Topalian Journal: J Clin Oncol Date: 2019-02-06 Impact factor: 44.544